奥氮平与齐拉西酮治疗精神分裂症急性期的对照研究.docVIP

精品论文 参考文献 奥氮平与齐拉西酮治疗精神分裂症急性期的对照研究 李娟 章飞杰 杨美娟 刘健华 冯龙喜（江苏省大丰市第二人民医院 江苏大丰 224100） 【摘要】目的 评价奥氮平、齐拉西酮治疗精神分裂症的疗效和安全性。方法 将60例精神分裂症急性发作的患者随机分为奥氮平组(n=30)、齐拉西酮组(n=30)，分别给予奥氮平、齐拉西酮单药治疗6周。在治疗前及治疗后第2、4、6周末采用阳性阴性症状量表(PANSS)评定其疗效、副反应量表(TESS)评定其不良反应。结果 治疗后2周奥氮平组PANSS总分显著下降(Plt;0.01)，治疗后4、6周各组的PANSS总分均有显著下降(P＜0.01)。奥氮平组的主要不良反应为嗜睡、便秘、体重增加及肝功能异常；齐拉西酮组的主要不良反应为锥体外系不良反应(EPS)、嗜睡、兴奋激越。结论 奥氮平、齐拉西酮治疗精神分裂症急性发作的疗效相当，但奥氮平起效较快，两种药物不良反应总体较轻。 【关键词】 精神分裂症 奥氮平 齐拉西酮 【中图分类号】R749.053【文献标识码】A【文章编号】2095-1752（2012）34-0196-02 A comparative study of olanzapine and ziprasidone in the treatment of acute-episode schizophrenia. LI juan. 【Abstrct】objective The study was designed to evaluate the efficacy and safety of olanzapine and ziprasidone in hospitalized patients with acute-episode schizophrenia. Methods 60 patients with CCMD-3 schizophrenia were randomized into olanzapine group (n=30) and ziprasidone group (n=30) treatment in a 6-week parallel-group study. The efficacy and side effects were assessed with the Positive and Negative Syndrome Scale (PANSS) ,Treatment Emergent Symptom Scale (TESS) at the end of the 2nd, 4th and 6th week of treatment. Results Olanzapine group demonstrated a significant decrease in PANSS score (Plt;0.01) at the end of 2nd week of treatment. Olanzapine group and ziprasidone group had a significant decrease in PANSS score at the end of 4th and 6th week of treatment. (Plt;0.01) . The common adverse events were somnolence, constipation, abnormal liver function and body weight increasing in olanzapine group, and extrapyremidal symptoms, somnolence, excitement and agitation in ziprasidone group. Conclusion Olanzapine and ziprasidone are similarly effective in significantly improving the symptoms in patients with acute-episode schizophrenia. The onset of the action of olanzapine is fast compared with that of ziprasidone. The adverse drug reaction of the two atypical antipsychotics is less in general. 【Key words】 Schizophrenia Olanzapine Ziprasi